NCT04098068

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will be looking at whether MK-3475 (pembrolizumab) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype.

Conditions

• High Tumor Mutation Burden
• High TMB (Tumor Mutation Burden)
• MSS (Microsatellite Stable)

Interventions

Type	Name	Description
DRUG	MK-3475	MK-3475 (pembrolizumab) 200 mg flat dose every 21 days

Timeline

• Start date: 2018-01-25
• Primary completion: 2022-05-15
• Completion: 2025-02-05
• First posted: 2019-09-20
• Last updated: 2025-03-30
• Results posted: 2023-05-19

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study